BRAIN CANCER

Timothy F. Cloughesy, MD, director of UCLA’s neuro-oncology program and distinguished professor in neurology, discusses the mechanism of action of vorasidenib.

The study will evaluate silmitasertib, a novel agent, for the treatment of pediatric and adult patients with relapsed/refractory solid tumors.

In an interview, Timothy F. Cloughesy, MD, discussed the recent approval of vorasidenib in IDH-mutant gliomas and data from the phase 3 INDIGO trial.

Timothy F. Cloughesy, MD, discusses the impact and significance of the FDA’s approval of vorasidenib, a first-in-class option for the treatment of patients with IDH-mutant gliomas.

The FDA has granted approval to vorasidenib for the treatment of patients with IDH-mutant diffuse glioma.

The FDA has granted expanded access to TLX101-CDx, a promising PET imaging agent for diagnosing and monitoring glioma.

Vincent Law, research associate at Moffitt Cancer Center, discusses the key takeaways and implications of this research.

Barbara O'Brien, MD, discusses the goals and results of a study investigating tucatinib, trastuzumab, and capecitabine for the treatment of leptomeningeal metastases in patients with HER2-positive breast cancer.

Mina Lobbous, MD, MPH, discusses findings and implications fro a study investigating a new regimen for the treatment of brain metastases in patients with HER2-positive breast cancer.

Christopher Moertel, MD, discusses mirdametinib's mechanism of action and the implications of the phase 2b ReNeu trial of the agent in NF1-associated plexiform neurofibroma.

The FDA has granted a fast track designation to AGuIX, a gadolinium-based nanodrug currently under evaluation for treating malignant gliomas and glioblastoma.

In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.

Deric Park, MD, discusses what challenges remain in treating glioblastoma, as well as new avenues for research in this difficult disease.

The FDA has approved the new drug application of tovorafenib for the treatment of pediatric low-grade glioma.

The FDA granted a fast track designation to olaptesed pegol with bevacizumab and radiotherapy for patients with newly diagnosed glioblastoma that is resistant to chemotherapy and where measurable tumor remains after surgery.

Findings from the phase 3 METIS trial found that tumor-treating fields were able to significantly improve time to intracranial progression in patients with brain metastases from non-small cell lung cancer.

A novel CAR T-cell therapy being developed at City of Hope offers a potential new treatment avenue for patients with recurrent glioblastoma and high-grade glioma. 

The FDA approved the investigational new drug application for olaptesed pegol as a potential treatment for adult patients with aggressive brain cancer, specifically glioblastoma.

The FDA has accepted and granted priority review for the new drug application for vorasidenib for the treatment of IDH-mutant diffuse glioma, with a PDUFA action date set for August 20, 2024.

Combining olaptesed pegol with bevacizumab and radiotherapy showed a 10-fold improvement in survival rate compared with the standard-of-care among patients with glioblastoma.

The FDA completed an advice meeting with the manufacturer of olaptesed pegol in anticipation of the filing of an investigational new drug application in Q1 of 2024.

A Safe to Proceed letter from the FDA has been granted to the investigational new drug application of a phase 2 study evaluating ropidoxuridine plus radiotherapy in patients with newly diagnosed IDH-wildtype glioblastoma.

The completion of the phase 1 trial is a crucial step toward making DOC1021 available to all patients with glioblastoma multiforme.

The median overall survival at 19 months of patients with glioblastoma continues to benefit from treatment with olaptesed pegol plus radiation and bevacizumab.

In an interview with Targeted Oncology, Yazmin Odia, MD, discussed the 3rd Annual Miami Cancer Institute Oncology Rehabilitation Symposium, including her discussion on incorporating rehabilitation into the course of treatment for patients with brain cancer.